Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ortiz, Stephan
1192  Ergebnisse:
Personensuche X
?
1

Immediate and sustained terminal complement inhibition with..:

Ortiz, Stephan ; Pittock, Sean J. ; Berthele, Achim...
Frontiers in Neurology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
2

Corrigendum to "The long-acting C5 inhibitor, ravulizumab, ..:

Ariceta, Gema ; Dixon, Bradley P. ; Kim, Seong Heon...
Kidney International.  104 (2023)  1 - p. 205 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Study design and methodology of the PREVAIL trial: a phase ..:

Howard, James ; Rakhade, Sanjay ; Scholz, Joachim...
Neurology.  100 (2023)  17_supplement_2 - p. , 2023
Link: https://doi.org/10.1212/..
 
?
4

Ravulizumab pharmacokinetics and pharmacodynamics in patien..:

Vu, Tuan ; Ortiz, Stephan ; Katsuno, Masahisa...
Journal of Neurology.  270 (2023)  6 - p. 3129-3137 , 2023
Link: https://doi.org/10.1007/..
 
?
5

Safety, tolerability, pharmacokinetics, pharmacodynamics an..:

Ortiz, Stephan ; McEneny, Alanna ; Amancha, Praveen...
Neurology.  100 (2023)  17_supplement_2 - p. , 2023
Link: https://doi.org/10.1212/..
 
?
6

Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adu..:

Ortiz, Stephan ; Pittock, Sean ; Berthele, Achim...
Neurology.  100 (2023)  17_supplement_2 - p. , 2023
Link: https://doi.org/10.1212/..
 
?
7

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizuma..:

Yenerel, Mustafa N. ; Sicre de Fontbrune, Flore ; Piatek, Caroline...
Advances in Therapy.  40 (2022)  1 - p. 211-232 , 2022
Link: https://doi.org/10.1007/..
 
?
8

Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adu..:

Vu, Tuan ; Ortiz, Stephan ; Katsuno, Masahisa...
Neurology.  98 (2022)  18_supplement - p. , 2022
Link: https://doi.org/10.1212/..
 
?
9

One‐year outcomes from a phase 3 randomized trial of ravuli..:

Kulasekararaj, Austin G. ; Hill, Anita ; Langemeijer, Saskia...
European Journal of Haematology.  106 (2021)  3 - p. 389-397 , 2021
Link: https://doi.org/10.1111/..
 
?
10

The long-acting C5 inhibitor, ravulizumab, is effective and..:

Ariceta, Gema ; Dixon, Bradley P. ; Kim, Seong Heon...
Kidney International.  100 (2021)  1 - p. 225-237 , 2021
Link: https://doi.org/10.1016/..
 
?
11

One-year efficacy and safety of ravulizumab in adults with ..:

Schrezenmeier, Hubert ; Kulasekararaj, Austin ; Mitchell, Lindsay...
Therapeutic Advances in Hematology.  11 (2020)  - p. 204062072096613 , 2020
Link: https://doi.org/10.1177/..
 
?
12

Correction to: The long-acting C5 inhibitor, ravulizumab, i..:

Tanaka, Kazuki ; Adams, Brigitte ; Aris, Alvaro Madrid...
Pediatric Nephrology.  36 (2020)  4 - p. 1033-1033 , 2020
Link: https://doi.org/10.1007/..
 
?
13

A Phase 3 Open-label, Randomized, Controlled Study to Evalu..:

Smith, Keisha ; Pace, Amy ; Ortiz, Stephan..
Trials.  21 (2020)  1 - p. , 2020
Link: https://doi.org/10.1186/..
 
?
14

The long-acting C5 inhibitor, ravulizumab, is efficacious a..:

Tanaka, Kazuki ; Adams, Brigitte ; Aris, Alvaro Madrid...
Pediatric Nephrology.  36 (2020)  4 - p. 889-898 , 2020
Link: https://doi.org/10.1007/..
 
?
15

The long-acting C5 inhibitor, Ravulizumab, is effective and..:

Rondeau, Eric ; Scully, Marie ; Ariceta, Gema...
Kidney International.  97 (2020)  6 - p. 1287-1296 , 2020
Link: https://doi.org/10.1016/..
 
1-15